This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma
BMC Cancer Open Access 15 April 2020
-
The Time Has Come for Targeted Therapies for AML: Lights and Shadows
Oncology and Therapy Open Access 24 January 2020
-
Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q
Scientific Reports Open Access 28 November 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Accession codes
References
The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059–2074.
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016; 374: 2209–2221.
Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739–744.
Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225–234.
Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553–567.
Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012; 483: 484–488.
Inoue S, Li WY, Tseng A, Beerman I, Elia AJ, Bendall SC et al. Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2. Cancer Cell 2016; 30: 337–348.
Cairns RA, Mak TW . Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov 2013; 3: 730–741.
Chen C, Liu Y, Lu C, Cross JR, Morris JP, Shroff AS et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev 2013; 27: 1974–1985.
Kats LM, Reschke M, Taulli R, Pozdnyakova O, Burgess K, Bhargava P et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell 2014; 14: 329–341.
Stein EM . IDH2 inhibition in AML: finally progress? Best Pract Res Clin Haematol 2015; 28: 112–115.
Birendra KC, DiNardo CD . Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG-120. Clin Lymphoma Myeloma Leuk 2016; 16: 460–465.
Graham SM, Vass JK, Holyoake TL, Graham GJ . Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells 2007; 25: 3111–3120.
Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR . A stem cell molecular signature. Science 2002; 298: 601–604.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545–15550.
Acknowledgements
This work was funded by project and program grants (RWJ and LMK) from the National Health and Medical Research Council of Australia (NHMRC) and a grant from the Peter Mac Foundation (LMK). RWJ was supported by an NHMRC Fellowship and LMK was supported by a Victorian Cancer Agency fellowship.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
RN and KEY are employees of and have ownership interest (including some with patents) in Agios Pharmaceuticals. The remaining authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Kats, L., Vervoort, S., Cole, R. et al. A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML. Leukemia 31, 1466–1470 (2017). https://doi.org/10.1038/leu.2017.84
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2017.84
This article is cited by
-
Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma
BMC Cancer (2020)
-
Oncometabolites in renal cancer
Nature Reviews Nephrology (2020)
-
The Time Has Come for Targeted Therapies for AML: Lights and Shadows
Oncology and Therapy (2020)
-
Updates on DNA methylation modifiers in acute myeloid leukemia
Annals of Hematology (2020)
-
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Nature Reviews Clinical Oncology (2018)